论文部分内容阅读
目的 研究多巴胺 (DA)D1受体拮抗剂SCH 2 3390和D2受体拮抗剂Eticlopride对可逆性局灶性脑缺血梗塞体积及皮层半暗带脑血流的影响。方法 采用激光多普勒脑血流计测量大鼠可逆性局灶性脑缺血各时相皮层半暗带脑血流 ,并于缺血后 2 4小时断头取脑切片 ,TTC染色 ,计算机图样分析系统测量脑梗塞体积。结果 D1受体拮抗剂SCH 2 3390可明显缩小局灶性脑缺血梗塞体积 ,改善缺血期各时相皮层半暗带脑血流。D2受体拮抗剂Eticlopride无此作用。结论 脑缺血时 ,D1受体参与了DA兴奋性毒性的介导 ,而与D2受体无关。D1受体拮抗剂SCH 2 3390具有抗脑缺血损伤作用。改善局部脑血流是其保护缺血大脑机制之一
Objective To investigate the effects of dopamine (DA) D1 receptor antagonist SCH 2 3390 and D2 receptor antagonist Eticlopride on reversible focal cerebral ischemic infarct volume and cortical cerebral blood flow. Methods Cerebral blood flow in the penumbra of rats with reversible focal cerebral ischemia and focal cerebral ischemia was measured by laser Doppler cerebral blood flow. The brain sections were cut off at 24 hours after ischemia, TTC staining, Pattern analysis system measures infarct volume. Results D1 receptor antagonist SCH 2 3390 could significantly reduce the volume of focal ischemic infarction and improve the cerebral blood flow in the penumbra of ischemic period. D2 receptor antagonist Eticlopride no such effect. Conclusions Cerebral ischemia, D1 receptor involved in the excitotoxicity of DA mediated, but not with the D2 receptor. D1 receptor antagonist SCH 2 3390 has an anti-ischemic effect. Improving local cerebral blood flow is one of the mechanisms that protects the ischemic brain